Recognized as“The Best CMO in China”at the Asia-Pacific Bio- processing Excellence Awards 2018.
First 6 x 5,000L Bioreactor Facilities GMP Certified in China.
Renamed to Sunshine Guojian Pharma, Launching New Business Model as a CDMO Focusing only on the Development and Manu- facturing of Biologics.
Construction of 6 x 5,000L Bioreactor Facilities Completed First in China.
First 2 x 3,000L Bioreactor Facilities GMP Certified in China.
JIANNIPAI®, a Biosimilar to Daclizumab, Approved in China.
National Engineering Research Center of Antibody Medicine (CMAB) Initiated and Established by Our Company.
YISAIPU®, the First Biosimilar to Enbrel®, Approved to Launch in China.
First 3 x 750L Bioreactor Facilities GMP Certified in China.
Founded as Citic Guojian.